PPARG and diabetes mellitus: In contrast, unlike ROS (an agonist of PPARγ) [59], 2 decreased the size of adipocytes but was irrelevant to the expression of lipogenic and lipolytic proteins (Figure 5); thus, 2 may show antidiabetic effects through a different mechanism of action than thiazolidinediones (TZDs) such as ROS, the drugs that are widely used to treat diabetes.